Acceleron Pharma Initiates Phase 2 Clinical Trial with ACE-031 in Patients with Duchenne Muscular Dystrophy

Acceleron Pharma has initiated its Phase 2 clinical trial of ACE-031. ACE-031 is an investigational protein therapy that builds muscle and increases strength by inhibiting signaling of a certain surface receptor. Though this trial specifically targets patients with Duchenne Muscular Dystrophy, the therapy holds potential for patients with ALS as well.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail